Alan joined Polaris Partners in 2002 and is a general partner focusing on building and investing in healthcare companies.  He has served as founder and/or has played a significant role as chairman and CEO in building five Polaris companies.

From 2006 to 2012, Alan has co-founded and served as CEO of Cerulean Pharma (a nanopharma­ceutical company based on technology from MIT and CalTech that is currently conducting clinical trials of its first product in oncology), co-founded Visterra (a protein prediction company targeting infectious disease), co-founded Calorics (a company focused on novel biology for diseases of aging), and co-founded XTuit (a company developing cancer drugs exploiting the tumor microenvironment).  From 2002 to 2006, Alan was President and CEO of Momenta Pharmaceuticals.  He joined Momenta as the fifth employee and built the company into a public company, creating an advanced and diversified pipeline, entering into two strategic col­laborations with Novartis, and raising $275 million. The first product from Momenta’s pipeline achieved over $1B during its first year of sales.

Prior to Polaris, Alan was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s stra­tegic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Among these products was Velcade® which became the main basis of the company’s $9B acquisition by Takeda.

Prior to Millennium, Alan was a marketing executive at Dupont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.